Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Pediatric Hematology/Oncology
•
Medical Oncology
•
Testicular Cancer
•
NCI-CCC Tumor Board Question
•
AYA
•
Johns Hopkins
•
NCI-CCC GU Tumor Board Question
Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?
Answer from: Medical Oncologist at Academic Institution
No.
Sign in or Register to read more
12828
Related Questions
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
When will you consider doing a biopsy of a potential metastatic site (lymph node, lung/visceral) for testicular cancer after orchiectomy?
Do you cap cisplatin dose in obese patients undergoing chemotherapy in germ cell tumors?
Would you recommend VIP x 4 cycles over EP x 4 cycles in a patient with good risk Stage IIIB seminoma but an elevated LDH over 5x upper limit of normal with a 20 pack year smoking history?
How do you differentiate demoralization from depression during cancer treatment?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
What treatment would you offer a patient with Down syndrome and stage IIA seminoma?
How do you manage critically ill poor risk mixed germ cell tumor patients presenting de novo with extensive lung metastases and severe respiratory failure?
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?